InvAscent partially exits Symbiotec Pharmalab via IPO, pre-IPO share sales

• InvAscent advised Rosewood Investment on a partial exit from Symbiotec Pharmalab via pre-IPO share sales, followed by the IPO.
• The partnership began with an INR 3.44 billion investment in December 2018; the fund retained a meaningful stake post-listing.
• Symbiotec manufactures corticosteroid, steroid-hormone APIs; it has expanded into CDMO services and complex injectables during the holding period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invascent published the original content used to generate this news brief on September 19, 2026, and is solely responsible for the information contained therein.